^
Association details:
| Biomarker: | EML6-ALK fusion + FBXO11-ALK fusion |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Novel EML6-ALK FBXO11-ALK Double Fusion Variant in Lung Adenocarcinoma and Response to Crizotinib
Excerpt:
The results showed a double ALK fusion, EML6 exon1-ALK exon20, and FBXO11 exon1-ALK exon20...The immunohistochemistry of ALK detection was 2+ (Fig. 1)...Crizotinib 250 mg twice daily was administered orally, and 1 month later, imaging re-examination revealed that the left pleural effusion had disappeared and the right hilar lymph node had decreased. Another 2 months later, the tumor continued to shrink (1.9 × 0.8 cm) (Fig. 2).
DOI:
10.1016/j.jtho.2018.07.011
